FRACP questions Flashcards
TIMI grading
hi flow oxygen in STEMI pts
NO unless hypoxic
Supplemental oxygen can have delterious effects in non-hypoxic patients
Types of AMI
PCI vs CABG in patient with ACS with left main artery disease only
GRACE score in ACS
Calculates 6month and 3 year mortality
TIMACS study
Re vascuarisatin in non culprit lesions on patients during PCI for STEMI?
YES!
Radial vs femoral access for coronary angiogram
Radial access related to signifcantly lower vascular complications reduction in all-cause mortality,
Contrast induced nephropathy not yet studied
Benefit of early intervention in high risk patients post thrombolysis
Dabigatran
Triple therapy in AF and ACS
Triple therapy, OAC, aspriin and clopridogrel for 6 months in patient post DES if low risk for bleeding
Which drug comibnation post-PCI is the safest in terms of future bleeding risk?
Low dose rivaroxaban plus DAPT
HOWEVER - these dosing regimens have not been formally investigated and are not FDA approved for AF or ACS
Evolocumab
Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin–kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%. Whether it prevents cardiovascular events is uncertain.
Ezetimibe added to statin therapy after ACS
Yes!
IMPROVE -IT!
Acute renal failure after angiogram